Balaxi Ventures Limited

Dated: June 10, 2020

To,
Listing Department,
National Stock Exchange of India Limited.
Exchange Plaza, Plot No C/1, G Block, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

Stock Code: **BALAXI**

Sub: Acquisitions made by Wholly Owned Subsidiary of the Company;

Dear Sir,

Pursuant to the earlier communication dated February 14, 2020, we would like to inform you that Balaxi Global DMCC, Dubai ("BGD") the Wholly Owned Subsidiary of Balaxi Ventures Limited ("BVL") has made the following acquisitions on June 09, 2020;

1. **Balaxi Healthcare Dominica SRL, Dominican Republic**

Balaxi Global DMCC, Dubai has acquired a Pharmaceutical Distribution Company, Balaxi Healthcare Dominica SRL ("BHD") in Dominican Republic in Central America. BHD is engaged in the distribution of Balaxi's Pharmaceutical Formulation Products in Dominican Republic.

BHD has 136 Pharmaceutical Formulation Products registered with the Ministry of Health (MOH), Dominican Republic. BHD has also applied for registration of further 48 products with the MOH of Dominican Republic, the approvals for which are expected in the coming months. All these products are supplied by Balaxi Ventures Limited/Balaxi Global DMCC, Dubai.

The enterprise valuation of BHD was fixed at USD 1.195 Million. After accounting for the liabilities, the cost of acquisition of equity shares is USD 14,564.

The Appointed Date for the acquisition was fixed as April 01, 2020. BHD is now a wholly owned subsidiary of BGD and a step down subsidiary of BVL.

BALAXI VENTURES LIMITED Hyderabad

Registered Office:
Plot No.409, H.No. 8-2-293, Maps Towers, 3rd Floor, Phase-III,
Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598
Phone: +91 40 23555300 | Email: info@balaxiventures.in
Website: www.balaxiventures.in

2. **Balaxi Healthcare Guatemala S.A., Guatemala**

Balaxi Global DMCC, Dubai has acquired a Pharmaceutical Distribution Company, Balaxi Healthcare Guatemala S.A. ("BHG") in Republic of Guatemala in Central America. BHG is engaged in the distribution of Balaxi's Pharmaceutical Formulation Products in Guatemala.

BHG has 71 Pharmaceutical Formulation Products registered with the Ministry of Health (MOH), Guatemala. Application for registration of further 35 products are pending for approval with the MOH of Guatemala. It is also in the process of making applications for registration for 26 more products, the approvals for which are expected in the coming months. All these products are supplied by Balaxi Ventures Limited/Balaxi Global DMCC, Dubai.

The enterprise valuation of BHG was fixed at USD 1.005 Million. After accounting for the liabilities, the cost of acquisition of equity shares is USD 15,000.

The Appointed Date for the acquisition was fixed as April 01, 2020. BHG is now a wholly owned subsidiary of BGD and is also a step down subsidiary of BVL.

Details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are given in Annexure A & B to this letter.

This is for your information and record.

Yours Faithfully,
For, **Balaxi Ventures Limited,**

BALAXI VENTURES LIMITED Hyderabad

Ashish Maheshwari
Managing Director

Registered Office:
Plot No.409, H.No. 8-2-293, Maps Towers, 3rd Floor, Phase-III,
Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598
Phone: +91 40 23555300 | Email: info@balaxiventures.in
Website: www.balaxiventures.in

Annexure A

SL.No	Particulars	Balaxi Healthcare Dominica SRL
A	Name of the target entity, details in brief such as size, turnover etc.;	Balaxi Healthcare Dominica SRL ("BHD") Other details are provided in Page No: 1
B	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	Yes, The acquisition falls under the definition of related party transaction and the transaction was done at arm's length basis. Balaxi International DMCC was seller of the shares in BHD. Balaxi International DMCC is the WOS of Balaxi Holding LLP and the promoter group owns Balaxi Holding LLP.
C	Industry to which the entity being acquired belongs;	Pharmaceutical Distribution Company
D	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	BHD is engaged in the distribution of Balaxi's Pharmaceutical Formulation Products in Dominican Republic The above said activity is in line with the main objects of the parent listed company.
E	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
F	Indicative time period for completion of the acquisition;	Details are provided in Page No: 1

BALAXI VENTURES LIMITED Hyderabad

Registered Office:
Plot No.409, H.No. 8-2-293, Maps Towers, 3rd Floor, Phase-III,
Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598
Phone: +91 40 23555300 | Email: info@balaxiventures.in
Website: www.balaxiventures.in

H	Cost of acquisition or the price at which the shares are acquired;	Details are provided in Page No: 1
I	Percentage of shareholding / control acquired and / or number of shares acquired;	Balaxi Global DMCC, Dubai shall hold 100 % shareholding in the company
J	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Brief background along with other details are provided in Page No 1 Date of Incorporation: 18.11.2015 Turnover for the last three year; FY 2019: USD 641,336 FY 2018: USD 53,773 FY 2017: NIL

Yours Faithfully,
For, **Balaxi Ventures Limited,**

Ashish Maheshwari
Managing Director

BALAXI VENTURES LIMITED Hyderabad

Registered Office:
Plot No.409, H.No. 8-2-293, Maps Towers, 3rd Floor, Phase-III,
Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598
Phone: +91 40 23555300 | Email: info@balaxiventures.in
Website: www.balaxiventures.in

Annexure B

SL.No	Particulars	Balaxi Healthcare Guatemala S.A.
A	Name of the target entity, details in brief such as size, turnover etc.;	Balaxi Healthcare Guatemala S.A. ("BHG") Other details are provided in Page No: 1
B	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	Yes, The acquisition falls under the definition of related party transaction and the transaction was done at arm's length basis. Balaxi International DMCC was seller of the shares in BHG. Balaxi International DMCC is the WOS of Balaxi Holding LLP and the promoter group owns Balaxi Holding LLP.
C	Industry to which the entity being acquired belongs;	Pharmaceutical Distribution Company
D	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	BHG is engaged in the distribution of Balaxi's Pharmaceutical Formulation Products in Republic of Guatemala The above said activity is in line with the Main Objects of the parent listed company.
E	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
F	Indicative time period for completion of the acquisition;	Details are provided in Page No: 1
G	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash Consideration

BALAXI VENTURES LIMITED Hyderabad

Registered Office:
Plot No.409, H.No. 8-2-293, Maps Towers, 3rd Floor, Phase-III,
Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598
Phone: +91 40 23555300 | Email: info@balaxiventures.in
Website: www.balaxiventures.in

G	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash Consideration
H	Cost of acquisition or the price at which the shares are acquired;	Details are provided in Page No: 1
I	Percentage of shareholding / control acquired and / or number of shares acquired;	Balaxi Global DMCC, Dubai shall hold 100 % shareholding in the company
J	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Brief background along with other details are provided in Page No 1 Date of Incorporation: 14.01.2009. Turnover for the last three year; FY 2019: USD 2,836,483 FY 2018: USD 2,511,792 FY 2017: USD 491,923

Yours Faithfully,
For, **Balaxi Ventures Limited,**

Ashish Maheshwari
Managing Director

BALAXI VENTURES LIMITED
Hyderabad

Registered Office:
Plot No.409, H.No. 8-2-293, Maps Towers, 3rd Floor, Phase-III,
Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598
Phone: +91 40 23555300 | Email: info@balaxiventures.in
Website: www.balaxiventures.in